Number |
Description of Exhibit
|
99.1 |
Press release: Tikcro Technologies Reports Third Quarter 2017 Results;
In-progress of Pre Clinical Trials of Full-Human CTLA-4 Antibodies, dated December 15, 2017.
|
TIKCRO TECHNOLOGIES LTD.
|
|||
|
By:
|
/s/ Aviv Boim | |
Date: December 18, 2017 |
Chief Executive Officer
|
||
Exhibit
Number
|
Description of Exhibit
|
Tikcro Technologies Ltd.
Condensed Balance Sheets
(US dollars in thousands)
|
September 30, 2017 |
December 31,
2016
|
|||||||
Unaudited
|
Audited
|
|||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$
|
6,735
|
$
|
7,507
|
||||
Receivables and other financial asset
|
110
|
89
|
||||||
Total current assets
|
6,845
|
7,596
|
||||||
Property and equipment, net
|
129
|
136
|
||||||
Total assets
|
$
|
6,974
|
$
|
7,732
|
||||
Liabilities and Shareholders' Equity
|
||||||||
Current liabilities
|
||||||||
Other current liabilities
|
$
|
337
|
$
|
237
|
||||
Shareholders' equity
|
6,637
|
7,495
|
||||||
Total liabilities and shareholders' equity
|
$
|
6,974
|
$
|
7,732
|
Tikcro Technologies Ltd.
Statements of Operations (US dollars in thousands, except per share data) |
Three Months Ended
September 30,
|
Nine Months Ended
September 30
|
|||||||||||||||
2017
|
2016
|
2017
|
2016
|
|||||||||||||
Research and development expenses
|
$
|
147
|
$
|
160
|
$
|
533
|
$
|
438
|
||||||||
General and administrative expenses, net
|
145
|
163
|
447
|
500
|
||||||||||||
Total operating expenses
|
292
|
323
|
980
|
938
|
||||||||||||
Operating loss
|
(292
|
)
|
(323
|
)
|
(980
|
)
|
(938
|
)
|
||||||||
Financial income (expenses), net
|
4
|
(2
|
)
|
6
|
(2
|
)
|
||||||||||
Net loss
|
$
|
(288
|
)
|
$
|
(325
|
)
|
$
|
(974
|
)
|
$
|
(940
|
)
|
||||
Basic and diluted net loss per share
|
$
|
(0.03
|
)
|
$
|
(0.03
|
)
|
$
|
(0.10
|
)
|
$
|
(0.10
|
)
|
||||
Weighted average number of shares used computing basic and diluted loss per share
|
9,879
|
9,879
|
9,879
|
9,879
|